Need help finding what you are looking for?
Contact Us
PUBLISHER: QYResearch | PRODUCT CODE: 1873695
PUBLISHER: QYResearch | PRODUCT CODE: 1873695
Malignant Mesothelioma Therapeutic - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
PUBLISHED:
PAGES: 133 Pages
DELIVERY TIME: 2-3 business days
SELECT AN OPTION
The global market for Malignant Mesothelioma Therapeutic was estimated to be worth US$ 377 million in 2024 and is forecast to a readjusted size of US$ 602 million by 2031 with a CAGR of 7.0% during the forecast period 2025-2031.
Mesothelioma is a type of cancer that develops from the thin layer of tissue that covers many of the internal organs (known as the mesothelium). Malignant mesothelioma is a cancer of the thin tissue (mesothelium) that lines the lung, chest wall, and abdomen. The major risk factor for mesothelioma is asbestos exposure.
The malignant mesothelioma therapeutics market is primarily driven by increasing asbestos exposure cases in developing nations and rising disease awareness among occupational workers. Significant advancements in immunotherapy and targeted therapies, particularly immune checkpoint inhibitors and VEGF inhibitors, are revolutionizing treatment outcomes. The FDA's accelerated approval pathway for orphan drugs and growing R&D investments in rare cancer treatments are further propelling market growth. Additionally, improved diagnostic techniques enabling earlier detection and a surge in biomarker-driven personalized medicine approaches are creating new therapeutic opportunities.
The market faces substantial hurdles including late-stage diagnosis in most patients, severely limiting treatment efficacy. High development costs for novel therapies and limited patient pools due to mesothelioma's rarity create commercial viability concerns for pharmaceutical companies. Stringent asbestos regulations in developed countries are reducing incident rates, paradoxically shrinking the addressable market. Furthermore, the lack of standardized treatment protocols and frequent chemotherapy resistance present significant clinical management challenges, while reimbursement issues for expensive emerging therapies restrict patient access in many healthcare systems.
This report aims to provide a comprehensive presentation of the global market for Malignant Mesothelioma Therapeutic, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Malignant Mesothelioma Therapeutic by region & country, by Type, and by Application.
The Malignant Mesothelioma Therapeutic market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Malignant Mesothelioma Therapeutic.
Market Segmentation
By Company
- Eli Lilly
- Teva
- Sanofi
- Bristol-Myers Squibb
- Pfizer
- Roche
- Merck
- Ono Pharmaceutical
- Mylan
- Fresenius Kabi
- Sun Pharmaceuticals
- Eagle Pharmaceuticals
- Qilu Pharma
- Sichuan Huiyu Pharma
- Nippon Kayaku
- Jiangsu Haosen
- Amgen
Segment by Type
- Pemetrexed
- Cisplatin
- Immunotherapy Agents
- Others
Segment by Application
- Pleural Mesothelioma
- Peritoneal Mesothelioma
- Others
By Region
- North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- South Korea
- Southeast Asia
- India
- Australia
- Rest of Asia-Pacific
- Europe
- Germany
- France
- U.K.
- Italy
- Netherlands
- Nordic Countries
- Rest of Europe
- Latin America
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
- Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Malignant Mesothelioma Therapeutic company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Malignant Mesothelioma Therapeutic in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Malignant Mesothelioma Therapeutic in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
Table of Contents
1 Market Overview
- 1.1 Malignant Mesothelioma Therapeutic Product Introduction
- 1.2 Global Malignant Mesothelioma Therapeutic Market Size Forecast (2020-2031)
- 1.3 Malignant Mesothelioma Therapeutic Market Trends & Drivers
- 1.3.1 Malignant Mesothelioma Therapeutic Industry Trends
- 1.3.2 Malignant Mesothelioma Therapeutic Market Drivers & Opportunity
- 1.3.3 Malignant Mesothelioma Therapeutic Market Challenges
- 1.3.4 Malignant Mesothelioma Therapeutic Market Restraints
- 1.4 Assumptions and Limitations
- 1.5 Study Objectives
- 1.6 Years Considered
2 Competitive Analysis by Company
- 2.1 Global Malignant Mesothelioma Therapeutic Players Revenue Ranking (2024)
- 2.2 Global Malignant Mesothelioma Therapeutic Revenue by Company (2020-2025)
- 2.3 Key Companies Malignant Mesothelioma Therapeutic Manufacturing Base Distribution and Headquarters
- 2.4 Key Companies Malignant Mesothelioma Therapeutic Product Offered
- 2.5 Key Companies Time to Begin Mass Production of Malignant Mesothelioma Therapeutic
- 2.6 Malignant Mesothelioma Therapeutic Market Competitive Analysis
- 2.6.1 Malignant Mesothelioma Therapeutic Market Concentration Rate (2020-2025)
- 2.6.2 Global 5 and 10 Largest Companies by Malignant Mesothelioma Therapeutic Revenue in 2024
- 2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Malignant Mesothelioma Therapeutic as of 2024)
- 2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
- 3.1 Introduction by Type
- 3.1.1 Pemetrexed
- 3.1.2 Cisplatin
- 3.1.3 Immunotherapy Agents
- 3.1.4 Others
- 3.2 Global Malignant Mesothelioma Therapeutic Sales Value by Type
- 3.2.1 Global Malignant Mesothelioma Therapeutic Sales Value by Type (2020 VS 2024 VS 2031)
- 3.2.2 Global Malignant Mesothelioma Therapeutic Sales Value, by Type (2020-2031)
- 3.2.3 Global Malignant Mesothelioma Therapeutic Sales Value, by Type (%) (2020-2031)
4 Segmentation by Application
- 4.1 Introduction by Application
- 4.1.1 Pleural Mesothelioma
- 4.1.2 Peritoneal Mesothelioma
- 4.1.3 Others
- 4.2 Global Malignant Mesothelioma Therapeutic Sales Value by Application
- 4.2.1 Global Malignant Mesothelioma Therapeutic Sales Value by Application (2020 VS 2024 VS 2031)
- 4.2.2 Global Malignant Mesothelioma Therapeutic Sales Value, by Application (2020-2031)
- 4.2.3 Global Malignant Mesothelioma Therapeutic Sales Value, by Application (%) (2020-2031)
5 Segmentation by Region
- 5.1 Global Malignant Mesothelioma Therapeutic Sales Value by Region
- 5.1.1 Global Malignant Mesothelioma Therapeutic Sales Value by Region: 2020 VS 2024 VS 2031
- 5.1.2 Global Malignant Mesothelioma Therapeutic Sales Value by Region (2020-2025)
- 5.1.3 Global Malignant Mesothelioma Therapeutic Sales Value by Region (2026-2031)
- 5.1.4 Global Malignant Mesothelioma Therapeutic Sales Value by Region (%), (2020-2031)
- 5.2 North America
- 5.2.1 North America Malignant Mesothelioma Therapeutic Sales Value, 2020-2031
- 5.2.2 North America Malignant Mesothelioma Therapeutic Sales Value by Country (%), 2024 VS 2031
- 5.3 Europe
- 5.3.1 Europe Malignant Mesothelioma Therapeutic Sales Value, 2020-2031
- 5.3.2 Europe Malignant Mesothelioma Therapeutic Sales Value by Country (%), 2024 VS 2031
- 5.4 Asia Pacific
- 5.4.1 Asia Pacific Malignant Mesothelioma Therapeutic Sales Value, 2020-2031
- 5.4.2 Asia Pacific Malignant Mesothelioma Therapeutic Sales Value by Region (%), 2024 VS 2031
- 5.5 South America
- 5.5.1 South America Malignant Mesothelioma Therapeutic Sales Value, 2020-2031
- 5.5.2 South America Malignant Mesothelioma Therapeutic Sales Value by Country (%), 2024 VS 2031
- 5.6 Middle East & Africa
- 5.6.1 Middle East & Africa Malignant Mesothelioma Therapeutic Sales Value, 2020-2031
- 5.6.2 Middle East & Africa Malignant Mesothelioma Therapeutic Sales Value by Country (%), 2024 VS 2031
6 Segmentation by Key Countries/Regions
- 6.1 Key Countries/Regions Malignant Mesothelioma Therapeutic Sales Value Growth Trends, 2020 VS 2024 VS 2031
- 6.2 Key Countries/Regions Malignant Mesothelioma Therapeutic Sales Value, 2020-2031
- 6.3 United States
- 6.3.1 United States Malignant Mesothelioma Therapeutic Sales Value, 2020-2031
- 6.3.2 United States Malignant Mesothelioma Therapeutic Sales Value by Type (%), 2024 VS 2031
- 6.3.3 United States Malignant Mesothelioma Therapeutic Sales Value by Application, 2024 VS 2031
- 6.4 Europe
- 6.4.1 Europe Malignant Mesothelioma Therapeutic Sales Value, 2020-2031
- 6.4.2 Europe Malignant Mesothelioma Therapeutic Sales Value by Type (%), 2024 VS 2031
- 6.4.3 Europe Malignant Mesothelioma Therapeutic Sales Value by Application, 2024 VS 2031
- 6.5 China
- 6.5.1 China Malignant Mesothelioma Therapeutic Sales Value, 2020-2031
- 6.5.2 China Malignant Mesothelioma Therapeutic Sales Value by Type (%), 2024 VS 2031
- 6.5.3 China Malignant Mesothelioma Therapeutic Sales Value by Application, 2024 VS 2031
- 6.6 Japan
- 6.6.1 Japan Malignant Mesothelioma Therapeutic Sales Value, 2020-2031
- 6.6.2 Japan Malignant Mesothelioma Therapeutic Sales Value by Type (%), 2024 VS 2031
- 6.6.3 Japan Malignant Mesothelioma Therapeutic Sales Value by Application, 2024 VS 2031
- 6.7 South Korea
- 6.7.1 South Korea Malignant Mesothelioma Therapeutic Sales Value, 2020-2031
- 6.7.2 South Korea Malignant Mesothelioma Therapeutic Sales Value by Type (%), 2024 VS 2031
- 6.7.3 South Korea Malignant Mesothelioma Therapeutic Sales Value by Application, 2024 VS 2031
- 6.8 Southeast Asia
- 6.8.1 Southeast Asia Malignant Mesothelioma Therapeutic Sales Value, 2020-2031
- 6.8.2 Southeast Asia Malignant Mesothelioma Therapeutic Sales Value by Type (%), 2024 VS 2031
- 6.8.3 Southeast Asia Malignant Mesothelioma Therapeutic Sales Value by Application, 2024 VS 2031
- 6.9 India
- 6.9.1 India Malignant Mesothelioma Therapeutic Sales Value, 2020-2031
- 6.9.2 India Malignant Mesothelioma Therapeutic Sales Value by Type (%), 2024 VS 2031
- 6.9.3 India Malignant Mesothelioma Therapeutic Sales Value by Application, 2024 VS 2031
7 Company Profiles
- 7.1 Eli Lilly
- 7.1.1 Eli Lilly Profile
- 7.1.2 Eli Lilly Main Business
- 7.1.3 Eli Lilly Malignant Mesothelioma Therapeutic Products, Services and Solutions
- 7.1.4 Eli Lilly Malignant Mesothelioma Therapeutic Revenue (US$ Million) & (2020-2025)
- 7.1.5 Eli Lilly Recent Developments
- 7.2 Teva
- 7.2.1 Teva Profile
- 7.2.2 Teva Main Business
- 7.2.3 Teva Malignant Mesothelioma Therapeutic Products, Services and Solutions
- 7.2.4 Teva Malignant Mesothelioma Therapeutic Revenue (US$ Million) & (2020-2025)
- 7.2.5 Teva Recent Developments
- 7.3 Sanofi
- 7.3.1 Sanofi Profile
- 7.3.2 Sanofi Main Business
- 7.3.3 Sanofi Malignant Mesothelioma Therapeutic Products, Services and Solutions
- 7.3.4 Sanofi Malignant Mesothelioma Therapeutic Revenue (US$ Million) & (2020-2025)
- 7.3.5 Sanofi Recent Developments
- 7.4 Bristol-Myers Squibb
- 7.4.1 Bristol-Myers Squibb Profile
- 7.4.2 Bristol-Myers Squibb Main Business
- 7.4.3 Bristol-Myers Squibb Malignant Mesothelioma Therapeutic Products, Services and Solutions
- 7.4.4 Bristol-Myers Squibb Malignant Mesothelioma Therapeutic Revenue (US$ Million) & (2020-2025)
- 7.4.5 Bristol-Myers Squibb Recent Developments
- 7.5 Pfizer
- 7.5.1 Pfizer Profile
- 7.5.2 Pfizer Main Business
- 7.5.3 Pfizer Malignant Mesothelioma Therapeutic Products, Services and Solutions
- 7.5.4 Pfizer Malignant Mesothelioma Therapeutic Revenue (US$ Million) & (2020-2025)
- 7.5.5 Pfizer Recent Developments
- 7.6 Roche
- 7.6.1 Roche Profile
- 7.6.2 Roche Main Business
- 7.6.3 Roche Malignant Mesothelioma Therapeutic Products, Services and Solutions
- 7.6.4 Roche Malignant Mesothelioma Therapeutic Revenue (US$ Million) & (2020-2025)
- 7.6.5 Roche Recent Developments
- 7.7 Merck
- 7.7.1 Merck Profile
- 7.7.2 Merck Main Business
- 7.7.3 Merck Malignant Mesothelioma Therapeutic Products, Services and Solutions
- 7.7.4 Merck Malignant Mesothelioma Therapeutic Revenue (US$ Million) & (2020-2025)
- 7.7.5 Merck Recent Developments
- 7.8 Ono Pharmaceutical
- 7.8.1 Ono Pharmaceutical Profile
- 7.8.2 Ono Pharmaceutical Main Business
- 7.8.3 Ono Pharmaceutical Malignant Mesothelioma Therapeutic Products, Services and Solutions
- 7.8.4 Ono Pharmaceutical Malignant Mesothelioma Therapeutic Revenue (US$ Million) & (2020-2025)
- 7.8.5 Ono Pharmaceutical Recent Developments
- 7.9 Mylan
- 7.9.1 Mylan Profile
- 7.9.2 Mylan Main Business
- 7.9.3 Mylan Malignant Mesothelioma Therapeutic Products, Services and Solutions
- 7.9.4 Mylan Malignant Mesothelioma Therapeutic Revenue (US$ Million) & (2020-2025)
- 7.9.5 Mylan Recent Developments
- 7.10 Fresenius Kabi
- 7.10.1 Fresenius Kabi Profile
- 7.10.2 Fresenius Kabi Main Business
- 7.10.3 Fresenius Kabi Malignant Mesothelioma Therapeutic Products, Services and Solutions
- 7.10.4 Fresenius Kabi Malignant Mesothelioma Therapeutic Revenue (US$ Million) & (2020-2025)
- 7.10.5 Fresenius Kabi Recent Developments
- 7.11 Sun Pharmaceuticals
- 7.11.1 Sun Pharmaceuticals Profile
- 7.11.2 Sun Pharmaceuticals Main Business
- 7.11.3 Sun Pharmaceuticals Malignant Mesothelioma Therapeutic Products, Services and Solutions
- 7.11.4 Sun Pharmaceuticals Malignant Mesothelioma Therapeutic Revenue (US$ Million) & (2020-2025)
- 7.11.5 Sun Pharmaceuticals Recent Developments
- 7.12 Eagle Pharmaceuticals
- 7.12.1 Eagle Pharmaceuticals Profile
- 7.12.2 Eagle Pharmaceuticals Main Business
- 7.12.3 Eagle Pharmaceuticals Malignant Mesothelioma Therapeutic Products, Services and Solutions
- 7.12.4 Eagle Pharmaceuticals Malignant Mesothelioma Therapeutic Revenue (US$ Million) & (2020-2025)
- 7.12.5 Eagle Pharmaceuticals Recent Developments
- 7.13 Qilu Pharma
- 7.13.1 Qilu Pharma Profile
- 7.13.2 Qilu Pharma Main Business
- 7.13.3 Qilu Pharma Malignant Mesothelioma Therapeutic Products, Services and Solutions
- 7.13.4 Qilu Pharma Malignant Mesothelioma Therapeutic Revenue (US$ Million) & (2020-2025)
- 7.13.5 Qilu Pharma Recent Developments
- 7.14 Sichuan Huiyu Pharma
- 7.14.1 Sichuan Huiyu Pharma Profile
- 7.14.2 Sichuan Huiyu Pharma Main Business
- 7.14.3 Sichuan Huiyu Pharma Malignant Mesothelioma Therapeutic Products, Services and Solutions
- 7.14.4 Sichuan Huiyu Pharma Malignant Mesothelioma Therapeutic Revenue (US$ Million) & (2020-2025)
- 7.14.5 Sichuan Huiyu Pharma Recent Developments
- 7.15 Nippon Kayaku
- 7.15.1 Nippon Kayaku Profile
- 7.15.2 Nippon Kayaku Main Business
- 7.15.3 Nippon Kayaku Malignant Mesothelioma Therapeutic Products, Services and Solutions
- 7.15.4 Nippon Kayaku Malignant Mesothelioma Therapeutic Revenue (US$ Million) & (2020-2025)
- 7.15.5 Nippon Kayaku Recent Developments
- 7.16 Jiangsu Haosen
- 7.16.1 Jiangsu Haosen Profile
- 7.16.2 Jiangsu Haosen Main Business
- 7.16.3 Jiangsu Haosen Malignant Mesothelioma Therapeutic Products, Services and Solutions
- 7.16.4 Jiangsu Haosen Malignant Mesothelioma Therapeutic Revenue (US$ Million) & (2020-2025)
- 7.16.5 Jiangsu Haosen Recent Developments
- 7.17 Amgen
- 7.17.1 Amgen Profile
- 7.17.2 Amgen Main Business
- 7.17.3 Amgen Malignant Mesothelioma Therapeutic Products, Services and Solutions
- 7.17.4 Amgen Malignant Mesothelioma Therapeutic Revenue (US$ Million) & (2020-2025)
- 7.17.5 Amgen Recent Developments
8 Industry Chain Analysis
- 8.1 Malignant Mesothelioma Therapeutic Industrial Chain
- 8.2 Malignant Mesothelioma Therapeutic Upstream Analysis
- 8.2.1 Key Raw Materials
- 8.2.2 Raw Materials Key Suppliers
- 8.2.3 Manufacturing Cost Structure
- 8.3 Midstream Analysis
- 8.4 Downstream Analysis (Customers Analysis)
- 8.5 Sales Model and Sales Channels
- 8.5.1 Malignant Mesothelioma Therapeutic Sales Model
- 8.5.2 Sales Channel
- 8.5.3 Malignant Mesothelioma Therapeutic Distributors
9 Research Findings and Conclusion
10 Appendix
- 10.1 Research Methodology
- 10.1.1 Methodology/Research Approach
- 10.1.1.1 Research Programs/Design
- 10.1.1.2 Market Size Estimation
- 10.1.1.3 Market Breakdown and Data Triangulation
- 10.1.2 Data Source
- 10.1.2.1 Secondary Sources
- 10.1.2.2 Primary Sources
- 10.1.1 Methodology/Research Approach
- 10.2 Author Details
- 10.3 Disclaimer
List of Tables
- Table 1. Malignant Mesothelioma Therapeutic Market Trends
- Table 2. Malignant Mesothelioma Therapeutic Market Drivers & Opportunity
- Table 3. Malignant Mesothelioma Therapeutic Market Challenges
- Table 4. Malignant Mesothelioma Therapeutic Market Restraints
- Table 5. Global Malignant Mesothelioma Therapeutic Revenue by Company (2020-2025) & (US$ Million)
- Table 6. Global Malignant Mesothelioma Therapeutic Revenue Market Share by Company (2020-2025)
- Table 7. Key Companies Malignant Mesothelioma Therapeutic Manufacturing Base Distribution and Headquarters
- Table 8. Key Companies Malignant Mesothelioma Therapeutic Product Type
- Table 9. Key Companies Time to Begin Mass Production of Malignant Mesothelioma Therapeutic
- Table 10. Global Malignant Mesothelioma Therapeutic Companies Market Concentration Ratio (CR5 and HHI)
- Table 11. Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Malignant Mesothelioma Therapeutic as of 2024)
- Table 12. Mergers & Acquisitions, Expansion Plans
- Table 13. Global Malignant Mesothelioma Therapeutic Sales Value by Type: 2020 VS 2024 VS 2031 (US$ Million)
- Table 14. Global Malignant Mesothelioma Therapeutic Sales Value by Type (2020-2025) & (US$ Million)
- Table 15. Global Malignant Mesothelioma Therapeutic Sales Value by Type (2026-2031) & (US$ Million)
- Table 16. Global Malignant Mesothelioma Therapeutic Sales Market Share in Value by Type (2020-2025)
- Table 17. Global Malignant Mesothelioma Therapeutic Sales Market Share in Value by Type (2026-2031)
- Table 18. Global Malignant Mesothelioma Therapeutic Sales Value by Application: 2020 VS 2024 VS 2031 (US$ Million)
- Table 19. Global Malignant Mesothelioma Therapeutic Sales Value by Application (2020-2025) & (US$ Million)
- Table 20. Global Malignant Mesothelioma Therapeutic Sales Value by Application (2026-2031) & (US$ Million)
- Table 21. Global Malignant Mesothelioma Therapeutic Sales Market Share in Value by Application (2020-2025)
- Table 22. Global Malignant Mesothelioma Therapeutic Sales Market Share in Value by Application (2026-2031)
- Table 23. Global Malignant Mesothelioma Therapeutic Sales Value by Region, (2020 VS 2024 VS 2031) & (US$ Million)
- Table 24. Global Malignant Mesothelioma Therapeutic Sales Value by Region (2020-2025) & (US$ Million)
- Table 25. Global Malignant Mesothelioma Therapeutic Sales Value by Region (2026-2031) & (US$ Million)
- Table 26. Global Malignant Mesothelioma Therapeutic Sales Value by Region (2020-2025) & (%)
- Table 27. Global Malignant Mesothelioma Therapeutic Sales Value by Region (2026-2031) & (%)
- Table 28. Key Countries/Regions Malignant Mesothelioma Therapeutic Sales Value Growth Trends, (US$ Million): 2020 VS 2024 VS 2031
- Table 29. Key Countries/Regions Malignant Mesothelioma Therapeutic Sales Value, (2020-2025) & (US$ Million)
- Table 30. Key Countries/Regions Malignant Mesothelioma Therapeutic Sales Value, (2026-2031) & (US$ Million)
- Table 31. Eli Lilly Basic Information List
- Table 32. Eli Lilly Description and Business Overview
- Table 33. Eli Lilly Malignant Mesothelioma Therapeutic Products, Services and Solutions
- Table 34. Revenue (US$ Million) in Malignant Mesothelioma Therapeutic Business of Eli Lilly (2020-2025)
- Table 35. Eli Lilly Recent Developments
- Table 36. Teva Basic Information List
- Table 37. Teva Description and Business Overview
- Table 38. Teva Malignant Mesothelioma Therapeutic Products, Services and Solutions
- Table 39. Revenue (US$ Million) in Malignant Mesothelioma Therapeutic Business of Teva (2020-2025)
- Table 40. Teva Recent Developments
- Table 41. Sanofi Basic Information List
- Table 42. Sanofi Description and Business Overview
- Table 43. Sanofi Malignant Mesothelioma Therapeutic Products, Services and Solutions
- Table 44. Revenue (US$ Million) in Malignant Mesothelioma Therapeutic Business of Sanofi (2020-2025)
- Table 45. Sanofi Recent Developments
- Table 46. Bristol-Myers Squibb Basic Information List
- Table 47. Bristol-Myers Squibb Description and Business Overview
- Table 48. Bristol-Myers Squibb Malignant Mesothelioma Therapeutic Products, Services and Solutions
- Table 49. Revenue (US$ Million) in Malignant Mesothelioma Therapeutic Business of Bristol-Myers Squibb (2020-2025)
- Table 50. Bristol-Myers Squibb Recent Developments
- Table 51. Pfizer Basic Information List
- Table 52. Pfizer Description and Business Overview
- Table 53. Pfizer Malignant Mesothelioma Therapeutic Products, Services and Solutions
- Table 54. Revenue (US$ Million) in Malignant Mesothelioma Therapeutic Business of Pfizer (2020-2025)
- Table 55. Pfizer Recent Developments
- Table 56. Roche Basic Information List
- Table 57. Roche Description and Business Overview
- Table 58. Roche Malignant Mesothelioma Therapeutic Products, Services and Solutions
- Table 59. Revenue (US$ Million) in Malignant Mesothelioma Therapeutic Business of Roche (2020-2025)
- Table 60. Roche Recent Developments
- Table 61. Merck Basic Information List
- Table 62. Merck Description and Business Overview
- Table 63. Merck Malignant Mesothelioma Therapeutic Products, Services and Solutions
- Table 64. Revenue (US$ Million) in Malignant Mesothelioma Therapeutic Business of Merck (2020-2025)
- Table 65. Merck Recent Developments
- Table 66. Ono Pharmaceutical Basic Information List
- Table 67. Ono Pharmaceutical Description and Business Overview
- Table 68. Ono Pharmaceutical Malignant Mesothelioma Therapeutic Products, Services and Solutions
- Table 69. Revenue (US$ Million) in Malignant Mesothelioma Therapeutic Business of Ono Pharmaceutical (2020-2025)
- Table 70. Ono Pharmaceutical Recent Developments
- Table 71. Mylan Basic Information List
- Table 72. Mylan Description and Business Overview
- Table 73. Mylan Malignant Mesothelioma Therapeutic Products, Services and Solutions
- Table 74. Revenue (US$ Million) in Malignant Mesothelioma Therapeutic Business of Mylan (2020-2025)
- Table 75. Mylan Recent Developments
- Table 76. Fresenius Kabi Basic Information List
- Table 77. Fresenius Kabi Description and Business Overview
- Table 78. Fresenius Kabi Malignant Mesothelioma Therapeutic Products, Services and Solutions
- Table 79. Revenue (US$ Million) in Malignant Mesothelioma Therapeutic Business of Fresenius Kabi (2020-2025)
- Table 80. Fresenius Kabi Recent Developments
- Table 81. Sun Pharmaceuticals Basic Information List
- Table 82. Sun Pharmaceuticals Description and Business Overview
- Table 83. Sun Pharmaceuticals Malignant Mesothelioma Therapeutic Products, Services and Solutions
- Table 84. Revenue (US$ Million) in Malignant Mesothelioma Therapeutic Business of Sun Pharmaceuticals (2020-2025)
- Table 85. Sun Pharmaceuticals Recent Developments
- Table 86. Eagle Pharmaceuticals Basic Information List
- Table 87. Eagle Pharmaceuticals Description and Business Overview
- Table 88. Eagle Pharmaceuticals Malignant Mesothelioma Therapeutic Products, Services and Solutions
- Table 89. Revenue (US$ Million) in Malignant Mesothelioma Therapeutic Business of Eagle Pharmaceuticals (2020-2025)
- Table 90. Eagle Pharmaceuticals Recent Developments
- Table 91. Qilu Pharma Basic Information List
- Table 92. Qilu Pharma Description and Business Overview
- Table 93. Qilu Pharma Malignant Mesothelioma Therapeutic Products, Services and Solutions
- Table 94. Revenue (US$ Million) in Malignant Mesothelioma Therapeutic Business of Qilu Pharma (2020-2025)
- Table 95. Qilu Pharma Recent Developments
- Table 96. Sichuan Huiyu Pharma Basic Information List
- Table 97. Sichuan Huiyu Pharma Description and Business Overview
- Table 98. Sichuan Huiyu Pharma Malignant Mesothelioma Therapeutic Products, Services and Solutions
- Table 99. Revenue (US$ Million) in Malignant Mesothelioma Therapeutic Business of Sichuan Huiyu Pharma (2020-2025)
- Table 100. Sichuan Huiyu Pharma Recent Developments
- Table 101. Nippon Kayaku Basic Information List
- Table 102. Nippon Kayaku Description and Business Overview
- Table 103. Nippon Kayaku Malignant Mesothelioma Therapeutic Products, Services and Solutions
- Table 104. Revenue (US$ Million) in Malignant Mesothelioma Therapeutic Business of Nippon Kayaku (2020-2025)
- Table 105. Nippon Kayaku Recent Developments
- Table 106. Jiangsu Haosen Basic Information List
- Table 107. Jiangsu Haosen Description and Business Overview
- Table 108. Jiangsu Haosen Malignant Mesothelioma Therapeutic Products, Services and Solutions
- Table 109. Revenue (US$ Million) in Malignant Mesothelioma Therapeutic Business of Jiangsu Haosen (2020-2025)
- Table 110. Jiangsu Haosen Recent Developments
- Table 111. Amgen Basic Information List
- Table 112. Amgen Description and Business Overview
- Table 113. Amgen Malignant Mesothelioma Therapeutic Products, Services and Solutions
- Table 114. Revenue (US$ Million) in Malignant Mesothelioma Therapeutic Business of Amgen (2020-2025)
- Table 115. Amgen Recent Developments
- Table 116. Key Raw Materials Lists
- Table 117. Raw Materials Key Suppliers Lists
- Table 118. Malignant Mesothelioma Therapeutic Downstream Customers
- Table 119. Malignant Mesothelioma Therapeutic Distributors List
- Table 120. Research Programs/Design for This Report
- Table 121. Key Data Information from Secondary Sources
- Table 122. Key Data Information from Primary Sources
List of Figures
- Figure 1. Malignant Mesothelioma Therapeutic Product Picture
- Figure 2. Global Malignant Mesothelioma Therapeutic Sales Value, 2020 VS 2024 VS 2031 (US$ Million)
- Figure 3. Global Malignant Mesothelioma Therapeutic Sales Value (2020-2031) & (US$ Million)
- Figure 4. Malignant Mesothelioma Therapeutic Report Years Considered
- Figure 5. Global Malignant Mesothelioma Therapeutic Players Revenue Ranking (2024) & (US$ Million)
- Figure 6. The 5 and 10 Largest Companies in the World: Market Share by Malignant Mesothelioma Therapeutic Revenue in 2024
- Figure 7. Malignant Mesothelioma Therapeutic Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
- Figure 8. Pemetrexed Picture
- Figure 9. Cisplatin Picture
- Figure 10. Immunotherapy Agents Picture
- Figure 11. Others Picture
- Figure 12. Global Malignant Mesothelioma Therapeutic Sales Value by Type (2020 VS 2024 VS 2031) & (US$ Million)
- Figure 13. Global Malignant Mesothelioma Therapeutic Sales Value Market Share by Type, 2024 & 2031
- Figure 14. Product Picture of Pleural Mesothelioma
- Figure 15. Product Picture of Peritoneal Mesothelioma
- Figure 16. Product Picture of Others
- Figure 17. Global Malignant Mesothelioma Therapeutic Sales Value by Application (2020 VS 2024 VS 2031) & (US$ Million)
- Figure 18. Global Malignant Mesothelioma Therapeutic Sales Value Market Share by Application, 2024 & 2031
- Figure 19. North America Malignant Mesothelioma Therapeutic Sales Value (2020-2031) & (US$ Million)
- Figure 20. North America Malignant Mesothelioma Therapeutic Sales Value by Country (%), 2024 VS 2031
- Figure 21. Europe Malignant Mesothelioma Therapeutic Sales Value, (2020-2031) & (US$ Million)
- Figure 22. Europe Malignant Mesothelioma Therapeutic Sales Value by Country (%), 2024 VS 2031
- Figure 23. Asia Pacific Malignant Mesothelioma Therapeutic Sales Value, (2020-2031) & (US$ Million)
- Figure 24. Asia Pacific Malignant Mesothelioma Therapeutic Sales Value by Region (%), 2024 VS 2031
- Figure 25. South America Malignant Mesothelioma Therapeutic Sales Value, (2020-2031) & (US$ Million)
- Figure 26. South America Malignant Mesothelioma Therapeutic Sales Value by Country (%), 2024 VS 2031
- Figure 27. Middle East & Africa Malignant Mesothelioma Therapeutic Sales Value, (2020-2031) & (US$ Million)
- Figure 28. Middle East & Africa Malignant Mesothelioma Therapeutic Sales Value by Country (%), 2024 VS 2031
- Figure 29. Key Countries/Regions Malignant Mesothelioma Therapeutic Sales Value (%), (2020-2031)
- Figure 30. United States Malignant Mesothelioma Therapeutic Sales Value, (2020-2031) & (US$ Million)
- Figure 31. United States Malignant Mesothelioma Therapeutic Sales Value by Type (%), 2024 VS 2031
- Figure 32. United States Malignant Mesothelioma Therapeutic Sales Value by Application (%), 2024 VS 2031
- Figure 33. Europe Malignant Mesothelioma Therapeutic Sales Value, (2020-2031) & (US$ Million)
- Figure 34. Europe Malignant Mesothelioma Therapeutic Sales Value by Type (%), 2024 VS 2031
- Figure 35. Europe Malignant Mesothelioma Therapeutic Sales Value by Application (%), 2024 VS 2031
- Figure 36. China Malignant Mesothelioma Therapeutic Sales Value, (2020-2031) & (US$ Million)
- Figure 37. China Malignant Mesothelioma Therapeutic Sales Value by Type (%), 2024 VS 2031
- Figure 38. China Malignant Mesothelioma Therapeutic Sales Value by Application (%), 2024 VS 2031
- Figure 39. Japan Malignant Mesothelioma Therapeutic Sales Value, (2020-2031) & (US$ Million)
- Figure 40. Japan Malignant Mesothelioma Therapeutic Sales Value by Type (%), 2024 VS 2031
- Figure 41. Japan Malignant Mesothelioma Therapeutic Sales Value by Application (%), 2024 VS 2031
- Figure 42. South Korea Malignant Mesothelioma Therapeutic Sales Value, (2020-2031) & (US$ Million)
- Figure 43. South Korea Malignant Mesothelioma Therapeutic Sales Value by Type (%), 2024 VS 2031
- Figure 44. South Korea Malignant Mesothelioma Therapeutic Sales Value by Application (%), 2024 VS 2031
- Figure 45. Southeast Asia Malignant Mesothelioma Therapeutic Sales Value, (2020-2031) & (US$ Million)
- Figure 46. Southeast Asia Malignant Mesothelioma Therapeutic Sales Value by Type (%), 2024 VS 2031
- Figure 47. Southeast Asia Malignant Mesothelioma Therapeutic Sales Value by Application (%), 2024 VS 2031
- Figure 48. India Malignant Mesothelioma Therapeutic Sales Value, (2020-2031) & (US$ Million)
- Figure 49. India Malignant Mesothelioma Therapeutic Sales Value by Type (%), 2024 VS 2031
- Figure 50. India Malignant Mesothelioma Therapeutic Sales Value by Application (%), 2024 VS 2031
- Figure 51. Malignant Mesothelioma Therapeutic Industrial Chain
- Figure 52. Malignant Mesothelioma Therapeutic Manufacturing Cost Structure
- Figure 53. Channels of Distribution (Direct Sales, and Distribution)
- Figure 54. Bottom-up and Top-down Approaches for This Report
- Figure 55. Data Triangulation
- Figure 56. Key Executives Interviewed
Have a question?
SELECT AN OPTION
Have a question?
Questions? Please give us a call or visit the contact form.